By Katherine Hamilton
Carisma Therapeutics plans to explore strategic alternatives after cutting 95% of its workforce.
The Philadelphia biotechnology company said Monday its board of directors approved a revised operating plan. The plan is aimed at maximizing the value of its assets and of potential future royalty payments from an agreement with Moderna.
The board in March approved cutting 42 full-time employees, which represents 95% of its total workforce, Carisma said in a filing with the Securities and Exchange Commission. That came after the company cut 62 jobs in 2024.
Strategic alternatives could include selling or licensing its assets, or merging with another company, Carisma said.
Carisma estimates it has cash and cash equivalents sufficient to fund operations into the second half of 2025.
Shares fell 6% to a 52-week low of 31 cents after markets closed Monday.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
March 31, 2025 17:24 ET (21:24 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。